FOXO Technologies Inc. (FOXO)
Company Description
FOXO Technologies Inc., a technology platform company, focuses on commercializing longevity science through products and services that serve the life insurance industry.
The company is developing products and services that combine longevity science with life insurance to support the consumer health and wellness engagement, and to simplify the consumer underwriting journey.
It offers FOXO Labs, a services platform that integrates saliva-based epigenetic biomarkers into accelerated underwriting protocols to improve the customer underwriting journey; and FOXO Life, an insurance products platform that offers proprietary life insurance products and third-party life insurance carrier products based on bundling longevity science with life insurance.
The company was founded in 2019 and is based in Minneapolis, Minnesota.
| Country | United States |
| IPO Date | Sep 16, 2022 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Seamus Lagan |
Contact Details
Address: 729 North Washington Avenue West Palm Beach, Minnesota United States | |
| Website | https://www.foxotechnologies.com |
Stock Details
| Ticker Symbol | FOXO |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001812360 |
| CUSIP Number | 351471305 |
| ISIN Number | US3514713052 |
| Employer ID | 85-1050265 |
| SIC Code | 6311 |
Key Executives
| Name | Position |
|---|---|
| Seamus Lagan | Chief Executive Officer & Director |
| Martin Christopher Ward FCA | Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 05, 2025 | S-1 | Filing |
| Jun 04, 2025 | 8-K | Current Report |
| Jun 02, 2025 | D | Filing |
| May 27, 2025 | DEF 14C | Filing |
| May 22, 2025 | D | Filing |
| May 20, 2025 | 10-Q | Quarterly Report |
| May 20, 2025 | 8-K | Current Report |
| May 15, 2025 | NT 10-Q | Filing |
| May 06, 2025 | 424B4 | Filing |
| May 06, 2025 | 8-K | Current Report |